<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">91757</article-id><article-id pub-id-type="doi">10.7554/eLife.91757</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.91757.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Circulating platelets modulate oligodendrocyte progenitor cell differentiation during remyelination</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Philp</surname><given-names>Amber R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Reyes</surname><given-names>Carolina R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9005-0313</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mansilla</surname><given-names>Josselyne</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Amar</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Chao</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Valenzuela-Krugmann</surname><given-names>Carlos</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0007-4825-5802</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Rawji</surname><given-names>Khalil S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9687-8330</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gonzalez Martinez</surname><given-names>Ginez A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Dimas</surname><given-names>Penelope</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hinrichsen</surname><given-names>Bryan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ulloa-Leal</surname><given-names>César</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Waller</surname><given-names>Amie K</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bessa de Sousa</surname><given-names>Diana M</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Castro</surname><given-names>Maite A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Aigner</surname><given-names>Ludwig</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ehrenfeld</surname><given-names>Pamela</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Maria Elena</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6236-7180</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kazanis</surname><given-names>Ilias</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ghevaert</surname><given-names>Cedric</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Franklin</surname><given-names>Robin JM</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rivera</surname><given-names>Francisco J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7895-6318</contrib-id><email>francisco.rivera@helsinki.fi</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/029ycp228</institution-id><institution>Laboratory of Stem Cells and Neuroregeneration, Institute of Anatomy, Histology and Pathology, Faculty of Medicine, Universidad Austral de Chile</institution></institution-wrap><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/029ycp228</institution-id><institution>Center for Interdisciplinary Studies on the Nervous System (CISNe), Universidad Austral de Chile</institution></institution-wrap><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>Wellcome-MRC Cambridge Stem Cell Institute &amp; Department of Clinical Neurosciences, University of Cambridge</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040af2s02</institution-id><institution>Translational Regenerative Neurobiology Group (TReN), Molecular and Integrative Biosciences Research Programme (MIBS), Faculty of Biological and Environmental Sciences, University of Helsinki</institution></institution-wrap><addr-line><named-content content-type="city">Helsinki</named-content></addr-line><country>Finland</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00txsqk22</institution-id><institution>Escuela de Ciencias Agrícolas y Veterinarias, Universidad Viña del Mar</institution></institution-wrap><addr-line><named-content content-type="city">Viña del Mar</named-content></addr-line><country>Chile</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>Department of Haematology and NHS Blood and Transplant, University of Cambridge</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03z3mg085</institution-id><institution>Institute of Molecular Regenerative Medicine, Paracelsus Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Salzburg</named-content></addr-line><country>Austria</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/029ycp228</institution-id><institution>Instituto de Bioquímica y Microbiología, Facultad de Ciencias, Universidad Austral de Chile</institution></institution-wrap><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/029ycp228</institution-id><institution>Laboratory of Cellular Pathology, Institute of Anatomy, Histology &amp; Pathology, Faculty of Medicine, Universidad Austral de Chile</institution></institution-wrap><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04ycpbx82</institution-id><institution>School of Life Sciences, University of Westminster</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ryu</surname><given-names>Vitaly</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Behrens</surname><given-names>Timothy E</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Altos Labs – Cambridge Institute of Science, Cambridge, United Kingdom</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>20</day><month>08</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP91757</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-08-28"><day>28</day><month>08</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-09-22"><day>22</day><month>09</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.09.20.558582"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-11-01"><day>01</day><month>11</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.91757.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-07-15"><day>15</day><month>07</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.91757.2"/></event></pub-history><permissions><copyright-statement>© 2023, Philp et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Philp et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-91757-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-91757-figures-v1.pdf"/><abstract><p>Revealing unknown cues that regulate oligodendrocyte progenitor cell (OPC) function in remyelination is important to optimise the development of regenerative therapies for multiple sclerosis (MS). Platelets are present in chronic non-remyelinated lesions of MS and an increase in circulating platelets has been described in experimental autoimmune encephalomyelitis (EAE) mice, an animal model for MS. However, the contribution of platelets to remyelination remains unexplored. Here we show platelet aggregation in proximity to OPCs in areas of experimental demyelination. Partial depletion of circulating platelets impaired OPC differentiation and remyelination, without altering blood-brain barrier stability and neuroinflammation. Transient exposure to platelets enhanced OPC differentiation in vitro, whereas sustained exposure suppressed this effect. In a mouse model of thrombocytosis (<italic>Calr<sup>+/-</sup></italic>), there was a sustained increase in platelet aggregation together with a reduction of newly-generated oligodendrocytes following toxin-induced demyelination. These findings reveal a complex bimodal contribution of platelet to remyelination and provide insights into remyelination failure in MS.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>multiple sclerosis</kwd><kwd>remyelination</kwd><kwd>oligodendrocyte progenitor cells</kwd><kwd>platelets</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd><kwd>Rat</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100020884</institution-id><institution>Agencia Nacional de Investigación y Desarrollo</institution></institution-wrap></funding-source><award-id>Fondecyt Regular Number 1201706 and Number 1161787</award-id><principal-award-recipient><name><surname>Rivera</surname><given-names>Francisco J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100020884</institution-id><institution>Agencia Nacional de Investigación y Desarrollo</institution></institution-wrap></funding-source><award-id>PCI Program Grant Number REDES170233</award-id><principal-award-recipient><name><surname>Rivera</surname><given-names>Francisco J</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100020884</institution-id><institution>Agencia Nacional de Investigación y Desarrollo</institution></institution-wrap></funding-source><award-id>PCI Program Grant Number REDES180139</award-id><principal-award-recipient><name><surname>Castro</surname><given-names>Maite A</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100020884</institution-id><institution>Agencia Nacional de Investigación y Desarrollo</institution></institution-wrap></funding-source><award-id>National Doctoral Fellowship Number 21170732</award-id><principal-award-recipient><name><surname>Philp</surname><given-names>Amber R</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100020884</institution-id><institution>Agencia Nacional de Investigación y Desarrollo</institution></institution-wrap></funding-source><award-id>National Doctoral Fellowship Number 21211727</award-id><principal-award-recipient><name><surname>Reyes</surname><given-names>Carolina R</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100020884</institution-id><institution>Agencia Nacional de Investigación y Desarrollo</institution></institution-wrap></funding-source><award-id>National Doctoral Fellowship Number 21221559</award-id><principal-award-recipient><name><surname>Valenzuela-Krugmann</surname><given-names>Carlos</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100020884</institution-id><institution>Agencia Nacional de Investigación y Desarrollo</institution></institution-wrap></funding-source><award-id>Fondecyt Regular Number 1201635</award-id><principal-award-recipient><name><surname>Ehrenfeld</surname><given-names>Pamela</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Transient platelet accumulation supports oligodendrocyte progenitor cell differentiation during myelin repair, while sustained exposure to elevated platelet numbers hampers the generation of remyelinating cells.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>In the CNS, remyelination by newly generated oligodendrocytes is largely mediated by the differentiation of oligodendrocyte progenitor cells (OPCs). In response to demyelination, OPCs proliferate, migrate, and differentiate into remyelinating oligodendrocytes (<xref ref-type="bibr" rid="bib12">Franklin and ffrench-Constant, 2008</xref>). Although remyelination represents a robust regenerative response to demyelination, it fails during the progress of multiple sclerosis (MS), a CNS autoimmune demyelinating disease (<xref ref-type="bibr" rid="bib31">Noseworthy et al., 2000</xref>). Unravelling the mechanisms that govern remyelination is essential to our understanding of why this important regenerative process fails in MS, as well as in guiding the development of regenerative therapies.</p><p>Platelets are small, anucleate cells essential for haemostatic plug formation (<xref ref-type="bibr" rid="bib39">Semple et al., 2011</xref>). Platelets also display tissue-regenerative properties (<xref ref-type="bibr" rid="bib32">Nurden, 2011</xref>). Several growth factors known to modulate OPCs’ responses to demyelination, such as PDGF and FGF2 (<xref ref-type="bibr" rid="bib45">Woodruff et al., 2004</xref>; <xref ref-type="bibr" rid="bib29">Murtie et al., 2005</xref>; <xref ref-type="bibr" rid="bib46">Zhou et al., 2006</xref>; <xref ref-type="bibr" rid="bib6">Clemente et al., 2011</xref>; <xref ref-type="bibr" rid="bib15">Hiratsuka et al., 2019</xref>), are stored in platelets (<xref ref-type="bibr" rid="bib5">Chen et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Lohmann et al., 2012</xref>; <xref ref-type="bibr" rid="bib38">Schallmoser and Strunk, 2013</xref>; <xref ref-type="bibr" rid="bib44">Warnke et al., 2013</xref>). We have previously shown that platelet lysate increases neural stem / progenitor cells (NSPCs) survival, an alternative but infrequent cellular source for mature oligodendrocytes (<xref ref-type="bibr" rid="bib16">Kazanis et al., 2015</xref>). Although this evidence argues in favour of a beneficial contribution of platelets to remyelination, other studies suggest a detrimental role. CD41-expressing platelets and platelet-contained molecules are found in non-remyelinated MS lesions (<xref ref-type="bibr" rid="bib24">Lock et al., 2002</xref>; <xref ref-type="bibr" rid="bib14">Han et al., 2008</xref>; <xref ref-type="bibr" rid="bib21">Langer et al., 2012</xref>; <xref ref-type="bibr" rid="bib41">Simon, 2012</xref>; <xref ref-type="bibr" rid="bib42">Steinman, 2012</xref>). Moreover, MS patients show increased levels of circulating platelet microparticles (PMPs) (<xref ref-type="bibr" rid="bib26">Marcos-Ramiro et al., 2014</xref>) and the number of PMPs are indicative of the clinical status of the disease (<xref ref-type="bibr" rid="bib36">Sáenz-Cuesta et al., 2014</xref>). Additionally, MS patients display high plasma levels of platelet-specific factors such as, P-selectin and PF4 that correlate with disease course and severity, respectively (<xref ref-type="bibr" rid="bib2">Cananzi et al., 1987</xref>; <xref ref-type="bibr" rid="bib20">Kuenz et al., 2005</xref>). In the animal model for MS, experimental autoimmune encephalomyelitis (EAE), platelet numbers within CNS increase (<xref ref-type="bibr" rid="bib9">D’Souza et al., 2018</xref>). When platelets were immunodepleted before clinical onset, EAE severity is decreased (<xref ref-type="bibr" rid="bib21">Langer et al., 2012</xref>; <xref ref-type="bibr" rid="bib17">Kocovski et al., 2019</xref>). Here, we ask whether circulating platelets regulate OPC function and how this impacts remyelination.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Circulating platelets transiently accumulate in response to demyelination and accumulate in close proximity to OPCs</title><p>We first assessed the distribution of platelets during remyelination. We created lysolecithin (LPC)-induced demyelinating lesions in the spinal cord white matter of wild type (WT) mice and collected tissue sections at 1-, 3-, 5-, 7-, 10, and 14 days post-lesion (dpl). We observed CD41+ platelet aggregates within and around the lesion early after demyelination (3 dpl) (p-value &lt;0.01; <xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). However, this was transient as platelet aggregates subsequently decreased until no aggregates were detected at 14 dpl (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). To assess whether platelet recruitment was specific to demyelination we injected PBS containing DAPI directly into the spinal cord. No signs of demyelination were observed under these conditions and platelet aggregation was minimal at 1- and 3 days post-PBS injection (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). We next evaluated the localization of platelets within the lesion. Large platelet aggregates were found within the blood vessels and within the tissue parenchyma at 5 dpl (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Platelets often localized with Olig2<sup>+</sup> cells around blood vessels, a scaffold used by OPCs for migration (<xref ref-type="bibr" rid="bib43">Tsai et al., 2016</xref>; <xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Platelets accumulate in response to demyelination.</title><p>(<bold>A</bold>) LPC induced demyelinating lesions in spinal cord white matter of WT mice at 1, 3, 7, and 14 dpl, stained for platelets (CD41<sup>+</sup>). Scale bar 100 μm. (<bold>B</bold>) Quantification of CD41<sup>+</sup> signal within the demyelinated lesion at 1 (n=<italic>6</italic>), 3 (n=<italic>5</italic>), 5 (n=<italic>5</italic>), 7 (n=<italic>6</italic>), 10 (n=4), and 14 dpl (n=<italic>4</italic>), and in NAWM (n=<italic>3</italic>). (<bold>C</bold>) Platelet staining (CD41<sup>+</sup>) in spinal cord white matter injected with PBS/DAPI. Scale bar 50 μm. (<bold>D</bold>) Upper left panel: localization of platelets within blood vessels (ColIV<sup>+</sup>) and in close proximity with OPCs (Olig2<sup>+</sup>) at 5 dpl. Upper right panel: IMARIS 3D projection shows the spatial distribution of platelets. Scale bar 10 μm. Lower panels: magnification of the IMARIS projection showing platelet aggregation within the blood (left panel) and penetration into the parenchyma (right panel). Scale bars: 5 μm (left panel) and 7 μm (right panel). Data were analysed using a Kruskal Wallis test. Data represent the mean ± SD. ** p&lt;0.01; ns (not significant), p&gt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91757-fig1-v1.tif"/></fig></sec><sec id="s2-2"><title>Depletion of circulating platelets alters OPC differentiation and remyelination in vivo</title><p>To investigate whether circulating platelets modulate OPC function in vivo, we used a platelet depletion model (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). LPC-induced focal demyelinating lesions were performed in WT mice followed by the administration of anti-CD42b at 3 dpl and every second day to prevent further platelet recruitment (<xref ref-type="bibr" rid="bib28">Morodomi et al., 2020</xref>; <xref ref-type="bibr" rid="bib8">de Sousa et al., 2023</xref>). We first confirmed that this depletion strategy leads to decreased numbers of recruited platelets, with no accumulation in the lesion (p-value &lt;0.05; <xref ref-type="fig" rid="fig2">Figure 2B</xref>). At 7 dpl, there was no difference in the number of Olig2<sup>+</sup> cells within the lesion between the platelet depleted and untreated group (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, upper panels, and D), indicating that platelets do not alter OPC recruitment in response to demyelination. Through the detection of CC1 expression, a marker that identifies mature oligodendrocytes (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, lower panels), we found that platelet depletion significantly decreased the number and percentage of Olig2<sup>+</sup>/CC1<sup>+</sup> cells compared to untreated mice (p-value &lt;0.05; <xref ref-type="fig" rid="fig2">Figure 2E and F</xref>), indicating that platelet depletion impairs OPC differentiation. Consistently, at 14 dpl we observed a significant decrease in the extent of remyelination (p-value &lt;0.01; <xref ref-type="fig" rid="fig2">Figure 2G and H</xref>) and the percentage of remyelinated axons compared to untreated animals (p-value &lt;0.05; <xref ref-type="fig" rid="fig2">Figure 2I</xref>). Previous studies have shown that decreasing the number of circulating platelets increases blood vessel leakiness (<xref ref-type="bibr" rid="bib7">Cloutier et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Gupta et al., 2020</xref>). To assess whether impaired OPC differentiation might be due to fibrinogen extravasation (<xref ref-type="bibr" rid="bib33">Petersen et al., 2017</xref>) or enhanced demyelination due to neutrophil infiltration (<xref ref-type="bibr" rid="bib35">Rüther et al., 2017</xref>), we evaluated their presence within the lesion parenchyma after platelet depletion. There were no significant differences between neutrophil (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A, B</xref>) and fibrinogen extravasation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C, D</xref>) after platelet depletion at 7 dpl, indicating that remyelination impairment likely derives from low numbers of circulating platelets rather than increased vascular leakiness.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Platelet depletion impairs remyelination in vivo.</title><p>(<bold>A</bold>) Schematic representation of the LPC-induced demyelination model coupled with platelet depletion using anti-CD42b. (<bold>B</bold>) Quantitative analysis of CD41<sup>+</sup> signal at 5 dpl in untreated (<italic>n=5</italic>) and platelet depleted mice (<italic>n=3</italic>). (<bold>C</bold>) Representative images of immunofluorescence staining of oligodendroglial lineage cells in untreated and platelet depleted mice at 7 dpl using Olig2<sup>+</sup> (upper panels) and mature oligodendrocytes using Olig2<sup>+</sup>/CC1<sup>+</sup> (lower panels). Boxed areas represent high magnification images. (<bold>D–F</bold>) Quantitative analysis of oligodendroglia at 7 dpl in untreated (n=<italic>3</italic>) and platelet depleted mice (n=<italic>5</italic>). (<bold>G</bold>) Representative images of toluidine blue staining of remyelination in untreated (<italic>n=6</italic>) and platelet depleted mice (<italic>n=3</italic>) at 14 dpl and (<bold>H–I</bold>) its quantification by relative ranking analysis. Data were analysed using an Unpaired Student’s t-test or Mann-Whitney U test. Data represent mean ± SD. * p&lt;0.05; ** p&lt;0.01; ns (not significant), p&gt;0.05. Scale bars, 100 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91757-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Platelet depletion does not alter BBB permeability.</title><p>(<bold>A</bold>) Representative immunofluorescence images of neutrophils (NIMP-R14<sup>+</sup>) and (<bold>B</bold>) number of neutrophils in LPC-induced white matter spinal cord lesion at 7 dpl in untreated (n=<italic>3</italic>) and platelet depleted mice (n=<italic>5</italic>). (<bold>C</bold>) Representative immunofluorescence images of Fibrinogen and (<bold>D</bold>) Quantification of Fibrinogen signal within the demyelinated lesion at 7 dpl in untreated and platelet depleted mice (n=<italic>4</italic>). Scale bar 50 μm. Data were analysed using an unpaired t-test. Data represent the mean ± SD. ns (not significant), p&gt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91757-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Changes in circulating platelet numbers does not alter the macrophage/microglia population during remyelination.</title><p>(<bold>A</bold>) Platelets (CD41<sup>+</sup>) are located in close proximity to the macrophage/microglia population (IBA-1<sup>+</sup>) at 5 dpl. Scale bar 10 μm. (<bold>B</bold>) Total macrophage/microglia population (IBA-1<sup>+</sup>), M1 (CD16/32<sup>+</sup>) and M2 (Arg-1<sup>+</sup>) cell subpopulations at 10 dpl. Scale bar 50 μm. (<bold>C–E</bold>) Quantitative analysis of total, M1 and M2 cell subpopulations in untreated (n=<italic>6</italic>), platelet depleted (n=<italic>3</italic>), and <italic>Calr<sup>+/-</sup></italic> mice (n=<italic>4</italic>). (<bold>F</bold>) Representative Oil-Red O staining of myelin debris at 10 dpl. (<bold>G</bold>) Quantification of Oil-Red O (ORO) staining in untreated (n=<italic>6</italic>) and platelet depleted mice (n=<italic>3</italic>). Scale bar 100 μm. Data were analysed using an ordinary one-way ANOVA and or an unpaired t-test. Data represent the mean ± SD. ns (not significant), p&gt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91757-fig2-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Depletion of circulating platelets does not alter macrophage/microglia numbers and polarization during remyelination</title><p>Blood-borne macrophages and CNS-resident microglia are essential for OPC differentiation during remyelination (<xref ref-type="bibr" rid="bib19">Kotter et al., 2006</xref>; <xref ref-type="bibr" rid="bib27">Miron et al., 2013</xref>). As platelets regulate macrophage function in neuroinflammation (<xref ref-type="bibr" rid="bib22">Langer and Chavakis, 2013</xref>; <xref ref-type="bibr" rid="bib3">Carestia et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Rolfes et al., 2020</xref>) and since platelets are located near macrophages/microglia upon demyelination (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>), we evaluated whether platelet depletion affects these cell populations (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>). At 10 dpl, platelet depletion did not alter the total number of IBA-1<sup>+</sup> (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>), pro-inflammatory IBA-1<sup>+</sup>/CD16/32<sup>+</sup> (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>) or anti-inflammatory IBA-1<sup>+</sup>/Arg-1<sup>+</sup> (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2E</xref>) macrophages/microglia present within the remyelinating lesion. Furthermore, platelet depletion did not influence macrophage/microglia phagocytic activity as no difference in myelin debris clearance, detected by Oil-Red O, was observed (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2F, G</xref>). Therefore, circulating platelets likely impact OPC differentiation without interfering with macrophage/microglia numbers/polarization during remyelination.</p></sec><sec id="s2-4"><title>Transient in vitro exposure to platelets enhances OPC differentiation</title><p>To confirm whether transient platelet exposure directly enhances OPC differentiation, OPCs were briefly exposed to washed platelets (WP) for 3 days (pulse) and differentiation was assessed 3 days after WP withdrawal. OPCs briefly exposed to 10% WP exhibited a significant increase in the percentage of Olig2<sup>+</sup>/MBP<sup>+</sup> mature oligodendrocytes compared to the vehicle treated control (p-value &lt;0.0001; <xref ref-type="fig" rid="fig3">Figure 3A and B</xref>), indicating that transient contact to platelets directly promotes OPC differentiation. Similar increases in the proportion of Olig2<sup>+</sup>/MBP<sup>+</sup> mature oligodendrocytes were observed when OPCs were transiently exposed to 1% platelet lysate (PL) compared to vehicle-treated control, indicating that this effect is, at least in part, mediated through platelet-contained factors and direct cell-cell contact is not essential (p-value &lt;0.05; <xref ref-type="fig" rid="fig3">Figure 3C, D</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Prolonged exposure to platelets suppresses their ability to enhance OPC differentiation.</title><p>(<bold>A</bold>) Representative fluorescence images of OPCs co-cultured with 1 (n=<italic>6</italic>), 5 (n=<italic>6</italic>), and 10% (n=<italic>6</italic>) washed platelets (WP) for 3 days in vitro (DIV), followed by WP removal for an additional 3 DIV (Pulse). Additionally, OPCs were co-cultured in the presence of 10% WP for 6 DIV (n=<italic>5</italic>) (Sustained). Vehicle treated OPCs represents the control condition (n=<italic>6</italic>). (<bold>B</bold>) Graph represents the percentage of Olig2<sup>+</sup>MBP<sup>+</sup> oligodendrocytes within the total Olig2 population (quantitative analysis of OPC differentiation). (<bold>C</bold>) Representative images of OPCs exposed to 1% platelet lysate (PL) (n=<italic>5</italic>) for 6 DIV. Vehicle treated OPCs represents the control condition (n=<italic>5</italic>). (<bold>D</bold>) Graph represents the quantitative analysis of OPC differentiation as in B. (<bold>E</bold>) Representative images of OPCs exposed to either PL for 9 DIV (Sustained) (n=<italic>5</italic>) or 6 DIV with PL followed by its removal for an additional 3 more DIV (Withdrawn) (n=<italic>5</italic>). Vehicle-treated OPCs represents the control condition (n=<italic>5</italic>). (<bold>F</bold>) Graph shows the quantitative analysis of OPC differentiation as in B and D. Data were analysed using one-way ANOVA followed by Tukey’s post-hoc test, a Mann-Whitney U test, or Kruskal-Wallis test. Data represent the mean ± SD. * p&lt;0.05; *** p&lt;0.001; **** p&lt;0.0001; ns (not significant), p&gt;0.05. Scale bars, 50 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91757-fig3-v1.tif"/></fig></sec><sec id="s2-5"><title>Sustained increase in circulating platelets hampers OPC differentiation during remyelination</title><p>Chronically-demyelinated MS lesions have been reported to contain a substantial number of platelets and their derived molecules (<xref ref-type="bibr" rid="bib24">Lock et al., 2002</xref>; <xref ref-type="bibr" rid="bib14">Han et al., 2008</xref>; <xref ref-type="bibr" rid="bib21">Langer et al., 2012</xref>; <xref ref-type="bibr" rid="bib41">Simon, 2012</xref>; <xref ref-type="bibr" rid="bib42">Steinman, 2012</xref>). To explore the effects of prolonged platelet exposure on OPC differentiation, we conducted experiments with sustained exposure to 10% WP. Contrary to the 3-day pulse-based exposure, 6 days of sustained exposure to 10% WP suppressed the ability of platelets to enhance OPC differentiation (p-value &lt;0.0001; <xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). Similar findings were observed upon 9 days of sustained exposure to 1% PL (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>), indicating effects mediated by platelet-contained factors. To test whether this effect is reversible, PL was withdrawn upon 6 days of sustained exposure, and OPC differentiation was evaluated 3 days later. Interestingly, PL withdrawal rescued the capability of platelets to enhance OPC differentiation when compared to the vehicle-treated control and the sustained condition (p-value &lt;0.05; <xref ref-type="fig" rid="fig3">Figure 3E, F</xref> - F).</p><p>To assess whether a permanent increase of circulating platelets may hamper OPC differentiation during remyelination, we used a conditional mouse knock-in model carrying a mutation within the calreticulin gene in a heterozygous fashion controlled by the Vav1 hematopoietic promoter, resulting in sustained thrombocytosis (2–3 times more circulating platelets) without alterations in other cell lineages (<xref ref-type="bibr" rid="bib23">Li et al., 2018</xref>). We induced a demyelinating lesion by LPC injection in the spinal cord white matter of <italic>Calr<sup>+/-</sup></italic> mice and evaluated platelet recruitment and OPC differentiation. As expected, at 5 and 10 dpl, <italic>Calr<sup>+/-</sup></italic> mice showed increased levels of circulating platelets (p-value &lt;0.01; <xref ref-type="fig" rid="fig4">Figure 4B</xref>) as well as a higher number of recruited platelets into the lesion (p-value &lt;0.05; <xref ref-type="fig" rid="fig4">Figure 4A and C</xref>). At 10 dpl, <italic>Calr<sup>+/-</sup></italic> mice displayed a reduced number of mature Olig2<sup>+</sup>/CC1<sup>+</sup> oligodendrocytes (<xref ref-type="fig" rid="fig4">Figure 4D and F</xref>) and a significant decrease in the percentage of differentiated OPCs (p-value &lt;0.05; <xref ref-type="fig" rid="fig4">Figure 4G</xref>) compared to WT mice, without alterations in the total number of Olig2<sup>+</sup> cells (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Additionally, we observed a negative correlation between the number of circulating platelets in <italic>Calr<sup>+/-</sup></italic> mice with the number of mature oligodendrocytes (<italic>r</italic>=–0.87, p-value &lt;0.01) (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). Similar to the platelet depleted model, effects on OPC differentiation are not mediated by inflammation, as <italic>Calr<sup>+/-</sup></italic> mice showed no alterations in macrophage/microglia numbers/polarization during remyelination (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B–E</xref>). These findings indicate that sustained exposure to platelets directly hampers OPC differentiation during remyelination.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>A sustained increase in circulating platelets impairs remyelination in-vivo.</title><p>(<bold>A</bold>) Representative fluorescence images of platelets (CD41<sup>+</sup>) in LPC induced demyelinating lesions of spinal cord white matter of WT and <italic>Calr <sup>+/-</sup></italic>mice at 5 and 10 dpl. Scale bar 50 μm. (<bold>B</bold>) Quantification of circulating platelets in WT vs <italic>Calr <sup>+/-</sup></italic>mice at 5 (n=4 and n=5, respectively) and 10 dpl (n=5 and n=6, respectively). (<bold>C</bold>) Quantification of CD41<sup>+</sup> signal in demyelinated lesions of WT vs <italic>Calr <sup>+/-</sup></italic>mice at 5 dpl (n=5 and n=<italic>5</italic>, respectively) and 10 dpl (n=4 and n=<italic>4</italic>, respectively). (<bold>D</bold>) Representative immunofluorescence staining of oligodendroglial lineage cells in untreated and platelet depleted mice at 10 dpl using Olig2<sup>+</sup> (upper panels) and mature oligodendrocytes using Olig2<sup>+</sup>/CC1<sup>+</sup> (lower panels) (n=<italic>4</italic>). Scale bar 100 μm. (<bold>E–G</bold>) Quantitative analysis of oligodendroglia at 10 dpl. (<bold>H</bold>) Correlation between the circulating platelet number with the number of Olig2<sup>+</sup>/CC1<sup>+</sup> cells within the demyelinated lesion. Data were analysed using a two-way ANOVA followed by Bonferroni’s post-hoc test, an unpaired t-test, Welch’s t-test, a Mann-Whitney U test, or Pearson’s correlation coefficient analysis. Data represent the mean ± SD. * p&lt;0.05; ** p&lt;0.01; ns (not significant), p&gt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91757-fig4-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In conclusion, our study reveals that in response to myelin damage platelets transiently accumulate within the vascular niche and locate near OPCs. While transient contact to platelets support OPC differentiation, long lasting exposure to elevated numbers of circulating platelets hampers the generation of oligodendrocytes during remyelination. These findings argue in favour of a beneficial physiological role of platelets in remyelination. However, we also highlight that sustained increased platelet counts, as occurs in MS-related conditions, negatively alter OPC function and contribute to remyelination failure in MS.</p><p>Although there is a need to reveal the underlying mechanism(s) by which platelets exert a bimodal action on OPC differentiation, our findings indicate that platelet-contained factors contribute to this effect. This study shows that the regeneration of oligodendrocytes rests on the transient vs sustained presence of platelets within demyelinated lesions. Platelet accumulation in MS lesions may result from blood-brain barrier damage (<xref ref-type="bibr" rid="bib1">Broman, 1964</xref>; <xref ref-type="bibr" rid="bib47">Zlokovic, 2008</xref>) and/or a clearance failure, but changes in their adhesiveness (<xref ref-type="bibr" rid="bib37">Sanders et al., 1968</xref>) and hyperactivity observed during MS (<xref ref-type="bibr" rid="bib40">Sheremata et al., 2008</xref>) may contribute to such scenario. Strategies that restore platelet function, spatially and temporally, represent a future step for developing regenerative therapies in MS.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD41 rat monoclonal</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab33661;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_726487">AB_726487</ext-link></td><td align="left" valign="bottom">Working dilution (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD16/32<break/>rat monoclonal</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat # BD 553142<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_394656">AB_394656</ext-link></td><td align="left" valign="bottom">Working dilution (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Iba-1 rabbit polyclonal</td><td align="left" valign="bottom">WAKO</td><td align="left" valign="bottom">Cat#<break/>019–19741;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_839504">AB_839504</ext-link></td><td align="left" valign="bottom">Working dilution (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Arg-1 goat polyclonal</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat# sc-18351;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2258542">AB_2258542</ext-link></td><td align="left" valign="bottom">Working dilution (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">NIMP-R14 rat monoclonal</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab2557;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_303154">AB_303154</ext-link></td><td align="left" valign="bottom">Working dilution (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Olig2 rabbit monoclonal</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# Ab109186;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10861310">AB_10861310</ext-link></td><td align="left" valign="bottom">Working dilution<break/>(1:200 in vivo)<break/>(1:500 in vitro)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CC1 mouse monoclonal</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat# OP80;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2057371">AB_2057371</ext-link></td><td align="left" valign="bottom">Working dilution (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">MBP rat monoclonal</td><td align="left" valign="bottom">Bio-rad</td><td align="left" valign="bottom">Cat# MCA409S;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_325004">AB_325004</ext-link></td><td align="left" valign="bottom">Working dilution (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Collagen IV (ColIV) goat polyclonal</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">CAT# AB769;<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_92262">AB_92262</ext-link></td><td align="left" valign="bottom">Working dilution (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Fibrinogen rabbit polyclonal</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat # ab34269<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_732367">AB_732367</ext-link></td><td align="left" valign="bottom">Working dilution (1:200)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-α-lysophosphatidylcholine</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat # L1381</td><td align="left" valign="bottom">Demyelinating agent, Working concentration 1%</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CD42b (mixture of rat monoclonal antibodies)</td><td align="left" valign="bottom">Emfret Analytics; <break/><xref ref-type="bibr" rid="bib10">Evans et al., 2021</xref></td><td align="left" valign="bottom">Cat #R300<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2721041">AB_2721041</ext-link></td><td align="left" valign="bottom">Platelet depletion antibody, Working concentration 0.6 μg/g</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse: C7BL/6</td><td align="left" valign="bottom">Charles River Laboratories</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003792">SCR_003792</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse: <italic>Calr</italic><sup>fl/+</sup>:Vav1-Cre mice</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib23">Li et al., 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Rattus norvegicus</italic>)</td><td align="left" valign="bottom">Rat:<break/>Sprague Dawley</td><td align="left" valign="bottom">Charles River Laboratories</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003792">SCR_003792</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p>All animal work at University of Cambridge complied with the requirements and regulations of the United Kingdom Home Office (Project Licenses PCOCOF291 and P667BD734). All the experiments at Universidad Austral de Chile were conducted in agreement with the Chilean Government’s Manual of Bioethics and Biosafety (CONICYT: The Chilean Commission of Scientific and Technological Research, Santiago, Chile) and according to the guidelines established by the Animal Protection Committee of the Universidad Austral de Chile (UACh). The animal study was reviewed and approved by the <italic>Comité Institucional de Cuidado y Uso de Animales (CICUA)-UACh</italic> (Report Number # 394/2020). All the experiments at University of Helsinki followed the guidelines posed by the Academy of Finland and the University of Helsinki on research ethics and integrity (under Internal License KEK23-022) and accordingly to the National Animal Ethics Committee of Finland (ELLA). Mice and rats had access to food and water ad libitum and were exposed to a 12 hr light cycle. For all in vivo studies animals were grouped randomly (treatment and time) as well as for all in vitro experiments.</p></sec><sec id="s4-2"><title>Human subjects</title><p>Human platelets were obtained from blood samples of healthy volunteers who signed a consent form before sampling. All procedures were approved by the <italic>Comité Ético y Científico del Servicio de Salud de Valdivia</italic> (CEC-SVS; ORD N° 510) to carry experiments at Universidad Austral de Chile and by the Ethical Committee of the University of Cambridge to perform experiments at this institution. The blood donors at Cambridge were approved by the human biology research ethics committee (reference number: HBREC.2018.13.).</p></sec><sec id="s4-3"><title>Focal demyelination lesions</title><p>A focal demyelinating lesion was induced in C57BL/6 and <italic>Calr<sup>+/-</sup></italic> mice between 2 and 4 months of age. Animals were anesthetized using Isoflurane/Oxygen (2–2.5%/1000 ml/min O<sub>2</sub>) and buprenorphine (0.05 mg/kg) was injected subcutaneously immediately before surgery. Local Lysolecithin-driven demyelination in mice was induced as previously described in <xref ref-type="bibr" rid="bib11">Fancy et al., 2009</xref>. Briefly, the spinal cord was exposed between two vertebrae of the thoracic column and demyelination was induced by injecting 1 µL of 1% lysolecithin (L-lysophosphatidylcholine, Sigma) into the ventral funiculus at a rate of approximately 0.5 µl/min<sup>–1</sup>. The incision was then sutured, and the animal was left to recover in a thermally controlled chamber. Animals were monitored for 72 hr after surgery. Any signs of pain, dragging of limbs, or weight loss of more than 15% of pre-surgery weight, resulted in cessation of the experiment. Mice were sacrificed at 1, 3, 5, 7, 10, and 14 dpl by transcardial perfusion of 4% PFA or glutaraldehyde under terminal anaesthesia.</p></sec><sec id="s4-4"><title>Platelet depletion</title><p>For platelet depletion, mice received an intraperitoneal injection (IP) of 0.6 µg/g of antiCD42b (Emfret Analytics) (<xref ref-type="bibr" rid="bib10">Evans et al., 2021</xref>), diluted in saline solution, at 3 dpl, followed by IP injections every 48 hr until the end of the experiment period. The effectiveness of platelet depletion was confirmed by measuring the number of circulating platelets using a VetAnalyzer (scil Vet abc Plus). Mice with a circulating platelet number below 200,000 platelets/µL were considered successfully depleted.</p></sec><sec id="s4-5"><title>Preparation of washed platelets and platelet lysate</title><p>Washed platelets (WP) were prepared as described (<xref ref-type="bibr" rid="bib4">Cazenave et al., 2004</xref>). Briefly, human blood samples were taken from the median cubital vein and collected in sodium citrate followed by centrifugation for 20 min at 120 x <italic>g</italic> to separate the red blood cells from the plasma. Plasma was collected and centrifuged at 1400 x <italic>g</italic> to pellet platelets. Plasma was removed without disrupting the platelet pellet. PGI<sub>2</sub> and sodium citrate were carefully added, followed by resuspension in Tyrode’s buffer. Platelet number was quantified using a Vet Analyzer and adjusted to a concentration of 1,000,000 platelets/µL. WP were used fresh, meanwhile for the platelet lysate (PL) preparation, the suspension underwent two freeze-thaw overnight cycles. Platelet fragments were then eliminated by centrifugation at 4000 x <italic>g</italic> for 15 min and the supernatant was collected and stored at - 20 °C.</p></sec><sec id="s4-6"><title>Primary OPC cultures</title><p>OPCs were obtained from Sprague-Dawley postnatal rats (p3 – p6) from both genders. Rat OPCs were isolated and prepared as described by <xref ref-type="bibr" rid="bib30">Neumann et al., 2019</xref>. Cells were then seeded onto glass plates pre-coated with Poly-D-Lysine (PDL) in 24-well plates, with a seeding density of 7000 cells for differentiation assays. For differentiation conditions, T3 was added to the culture media. All experimental conditions were replicated using two independent technical replicates. OPCs were either subjected to various concentrations of washed platelets (1%, 5%, and 10%) or to 1% of platelet lysate of the final volume.</p></sec><sec id="s4-7"><title>Histology and immunofluorescence</title><p>After transcardial perfusion with 4% PFA, tissue was post-fixed overnight in 4% PFA at 4 °C. After fixation, spinal cords were left in 30% sucrose overnight. Tissue was then embedded in OCT and cut in 15 µm transverse sections on a Leica Cryostat. Samples were stored at - 80 °C until use.</p><p>For immunofluorescence staining of tissues, samples were left to thaw for 30 min and washed with PBS. Samples were blocked for 1 hr, using a blocking solution that contained; 10% horse serum, 1% bovine serum albumin, 0.1% cold fish gelatine, 0.1% Triton X-100, and 0.05% Tween 20, diluted in PBS. After blocking, samples were incubated overnight at 4 °C with primary antibody diluted in PBS containing 1% bovine serum albumin, 0.1% cold fish gelatine, and 0.5% Triton X-100. The following primary antibodies were used: rat anti-CD41 (1:200 Abcam), rat anti-CD16/32 (1:200, BD Biosciences), rabbit anti-Fibrinogen (1:200, Abcam), rabbit anti-IBA1 (1:500, WAKO), goat anti-Collagen IV (ColIV) (1:100, Millipore), rabbit anti-Olig2 (1:200, Abcam), goat anti-Arg1 (1:200, Santa Cruz), mouse anti-CC1 (1:1000, Calbiochem), rat anti-NIMP-R14 (1:200, Abcam). Samples were washed three times for 5 min in PBS. After washing, samples were incubated with secondary antibody and DAPI for 1 hr, diluted in the same solution as the primary antibody. Samples were washed three times for 5 min in PBS. Samples were mounted with Fluromount. All secondary antibodies were diluted 1:500. For imaging of spinal cord tissue, the entire lesion area was imaged for five technical replicates.</p><p>For immunofluorescence staining of cell cultures, samples were initially washed three times with PBS for 5 min after fixation. The cells were then blocked with 10% Donkey Serum (DKS) in PBS for 1 hr, followed by incubation with the primary antibody overnight, diluted in the same blocking solution. The following primary antibodies were utilized: Rat Anti-Myelin Basic Protein (MBP; 1:500, Bio-Rad) and Rabbit Anti-Oligodendrocyte transcription factor 2 (Olig2; 1:500, Abcam). The cells were then washed three times with PBS 1 x for 5 min, followed by incubation with secondary antibodies, diluted in the blocking solution, for 1 hr. The cells were washed three more times with PBS 1 x for 5 min.</p><p>Images were captured using a Leica SP8 Laser Confocal, a Zeiss LSM 980 Confocal or an Olympus IX81FV1000. For cell culture imaging, 8–10 photos per well were quantified for each well using an automated macro in ImageJ/Fiji. For in vivo imaging, three to five photos were quantified per animal by a blinded observer. For tissue image analysis and 3D reconstruction of platelet localisation, ImageJ/Fiji (version 2.1.0/1.53 hr) and Imaris (Bitplane, version 9.3.1, and 9.9.0) were used.</p></sec><sec id="s4-8"><title>Oil-Red O staining</title><p>To analyse myelin debris clearance, tissue sections were stained with Oil-Red O as previously described by <xref ref-type="bibr" rid="bib18">Kotter et al., 2005</xref>. Briefly, sections were stained with freshly prepared Oil-Red O and incubated at 37 degrees for 30 min. Slides were washed and mounted using an aqueous mounting medium. Image J was used to threshold and quantify Oil-Red O images.</p></sec><sec id="s4-9"><title>Remyelination ranking analysis</title><p>For remyelination studies, tissue was fixed with 4% glutaraldehyde and embedded in resin. Semi-thin sections of the lesion were cut and stained with Toluidine Blue. Three blinded observers ranked the level of remyelination for each biological individual, giving the most remyelinated individual the highest score, and the individual with the lowest degree of remyelination the lowest. The average for each animal was calculated from the three independent observer rankings.</p></sec><sec id="s4-10"><title>Statistical analysis</title><p>Statistical analysis was performed using GraphPad Prism 10. In vivo data were obtained from three to six animals per groups (n value). In vitro studies were performed considering, at least, three technical replicates and statistical analysis was performed from five to six independent biological experiments (n value). The distribution of data were first tested using a Shapiro-Wilks test. Two-way ANOVA, One-way ANOVA or a Kruskal Wallis one-way analysis, with the corresponding post-hoc test, were used to compared multiple groups, and a Mann-Whitney U-test, an unpaired t-test or Welch’s t-test were used to compare between groups. Pearson’s correlation coefficient analysis was used for studies involving data correlation. p-Values were represented as *&lt;0.05, **&lt;0.01, ***&lt;0.001, ****&lt;0.0001.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Validation, Visualization, Writing – original draft, Writing – review and editing, Investigation</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Funding acquisition, Investigation, Methodology, Validation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Methodology, Validation, Writing – original draft</p></fn><fn fn-type="con" id="con4"><p>Methodology, Validation</p></fn><fn fn-type="con" id="con5"><p>Methodology, Validation, Writing – original draft</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Funding acquisition, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Methodology, Validation</p></fn><fn fn-type="con" id="con8"><p>Methodology</p></fn><fn fn-type="con" id="con9"><p>Methodology, Validation</p></fn><fn fn-type="con" id="con10"><p>Funding acquisition, Methodology</p></fn><fn fn-type="con" id="con11"><p>Methodology, Validation, Writing – original draft</p></fn><fn fn-type="con" id="con12"><p>Resources, Validation, Writing – original draft</p></fn><fn fn-type="con" id="con13"><p>Methodology, Project administration</p></fn><fn fn-type="con" id="con14"><p>Resources, Supervision, Methodology</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Resources, Supervision, Methodology</p></fn><fn fn-type="con" id="con16"><p>Resources, Supervision, Methodology, Validation</p></fn><fn fn-type="con" id="con17"><p>Supervision, Methodology, Validation, Writing – original draft</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Supervision, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Resources, Supervision, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Resources, Supervision, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con21"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Methodology, Project administration, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human platelets were obtained from blood samples of healthy volunteers who signed a consent form before sampling. All procedures were approved by the Comité Ético y Científico del Servicio de Salud de Valdivia (CEC-SVS) (ORD Nº 510) to carry experiments at Universidad Austral de Chile and by the Ethical Committee of the University of Cambridge to perform experiments at this institution. The blood donors at Cambridge were approved by the human biology research ethics committee (reference number: HBREC.2018.13.).</p></fn><fn fn-type="other"><p>All animal work at University of Cambridge complied with the requirements and regulations of the United Kingdom Home Office (Project Licenses PCOCOF291 and P667BD734). All the experiments at Universidad Austral de Chile were conducted in agreement with the Chilean Government's Manual of Bioethics and Biosafety (CONICYT: The Chilean Commission of Scientific and Technological Research, Santiago, Chile) and according to the guidelines established by the Animal Protection Committee of the Universidad Austral de Chile (UACh). The animal study was reviewed and approved by the Comité Institucional de Cuidado y Uso de Animales (CICUA)-UACh (Report Number # 394/2020). All the experiments at University of Helsinki followed the guidelines posed by the Academy of Finland and the University of Helsinki on research ethics and integrity (under Internal License KEK23-022) and accordingly to the National Animal Ethics Committee of Finland (ELLA). Mice and rats had access to food and water ad libitum and were exposed to a 12-hour light cycle. For all in vivo studies animals were grouped randomly (treatment and time) as well as for all in vitro experiments.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-91757-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All source data and pipelines for in vitro analysis can be found at: (1) <ext-link ext-link-type="uri" xlink:href="https://osf.io/8c9ef/?view_only=253f4298cf1440879f772329662419c1">https://osf.io/8c9ef/?view_only=253f4298cf1440879f772329662419c1</ext-link> and (2) <ext-link ext-link-type="uri" xlink:href="https://etsin.fairdata.fi/dataset/682e8b1f-2de3-4f8b-87fa-a3d157eda6c1">https://etsin.fairdata.fi/dataset/682e8b1f-2de3-4f8b-87fa-a3d157eda6c1</ext-link>.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Philp</surname><given-names>AR</given-names></name><name><surname>Reyes</surname><given-names>CR</given-names></name><name><surname>Mansilla</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Valenzuela-Krugmann</surname><given-names>C</given-names></name><name><surname>Rawji</surname><given-names>KS</given-names></name><name><surname>Gonzalez Martinez</surname><given-names>GA</given-names></name><name><surname>Dimas</surname><given-names>P</given-names></name><name><surname>Hinrichsen</surname><given-names>B</given-names></name><name><surname>Ulloa-Leal</surname><given-names>C</given-names></name><name><surname>Waller</surname><given-names>AK</given-names></name><name><surname>Bessa de Sousa</surname><given-names>DM</given-names></name><name><surname>Castro</surname><given-names>MA</given-names></name><name><surname>Aigner</surname><given-names>L</given-names></name><name><surname>Ehrenfeld</surname><given-names>P</given-names></name><name><surname>Silva</surname><given-names>ME</given-names></name><name><surname>Kazanis</surname><given-names>I</given-names></name><name><surname>Ghevaert</surname><given-names>C</given-names></name><name><surname>Franklin</surname><given-names>RJM</given-names></name><name><surname>Rivera</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Circulating Platelets Modulate Oligodendrocyte Progenitor Cell Differentiation During Remyelination</data-title><source>Open Science Framework</source><pub-id pub-id-type="doi">10.17605/OSF.IO/8C9EF</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Philp</surname><given-names>AR</given-names></name><name><surname>Reyes</surname><given-names>CR</given-names></name><name><surname>Mansilla</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Valenzuela-Krugmann</surname><given-names>C</given-names></name><name><surname>Rawji</surname><given-names>KS</given-names></name><name><surname>Gonzalez Martinez</surname><given-names>GA</given-names></name><name><surname>Dimas</surname><given-names>P</given-names></name><name><surname>Hinrichsen</surname><given-names>B</given-names></name><name><surname>Ulloa-Leal</surname><given-names>C</given-names></name><name><surname>Waller</surname><given-names>AK</given-names></name><name><surname>Bessa de Sousa</surname><given-names>DM</given-names></name><name><surname>Castro</surname><given-names>MA</given-names></name><name><surname>Aigner</surname><given-names>L</given-names></name><name><surname>Ehrenfeld</surname><given-names>P</given-names></name><name><surname>Silva</surname><given-names>ME</given-names></name><name><surname>Kazanis</surname><given-names>I</given-names></name><name><surname>Ghevaert</surname><given-names>C</given-names></name><name><surname>Franklin</surname><given-names>RJM</given-names></name><name><surname>Rivera</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Circulating Platelets Modulate Oligodendrocyte Progenitor Cell Differentiation During Remyelination</data-title><source>Fairdata IDA Etsin</source><pub-id pub-id-type="doi">10.23729/47130a30-4d3c-44ba-90fd-401ba4909213</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>Special acknowledgments to the <italic>Comité Ético y Científico del Servicio de Salud de Valdivia</italic> (CEC-SVS) for ethical guidance and approval (ORD N° 510). The authors thank the Laboratory of Chronobiology, UACh (led by Dr. Claudia Torres-Farfán) for supporting animal experimentation. We would also like to thank Dr. Alerie Guzman de la Fuente for the Fiji/ImageJ macro for in-vitro quantification. Authors thank the funding support from <italic>Agencia Nacional de Investigación y Desarrollo</italic> (ANID, Chile)-FONDECYT Program Regular Grant Numbers 1201706 and 1161787 (both to FJR), ANID-FONDECYT Program Regular Grant Number 1201635 (to PE), ANID-PCI Program Grant N° REDES170233 (to FJR) and N° REDES180139 (to MAC), ANID-National Doctoral Fellowship N° 21170732 (to ARP), N° 21211727 (to CRR) and N° 21221559 (to CVK). In addition, the authors thank the PROFI 6 N° 336234 of the Research Council of Finland.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broman</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1964">1964</year><article-title>Blood-brain barrier damage in multiple sclerosis supravital test-observations</article-title><source>Acta Neurologica Scandinavica. Supplementum</source><volume>40</volume><fpage>21</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0404.1964.tb04718.x</pub-id><pub-id pub-id-type="pmid">14196025</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cananzi</surname><given-names>AR</given-names></name><name><surname>Ferro-Milone</surname><given-names>F</given-names></name><name><surname>Grigoletto</surname><given-names>F</given-names></name><name><surname>Toldo</surname><given-names>M</given-names></name><name><surname>Meneghini</surname><given-names>F</given-names></name><name><surname>Bortolon</surname><given-names>F</given-names></name><name><surname>D’Andrea</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Relevance of platelet factor four (PF4) plasma levels in multiple sclerosis</article-title><source>Acta Neurologica Scandinavica</source><volume>76</volume><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0404.1987.tb03550.x</pub-id><pub-id pub-id-type="pmid">2960124</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carestia</surname><given-names>A</given-names></name><name><surname>Mena</surname><given-names>HA</given-names></name><name><surname>Olexen</surname><given-names>CM</given-names></name><name><surname>Ortiz Wilczyñski</surname><given-names>JM</given-names></name><name><surname>Negrotto</surname><given-names>S</given-names></name><name><surname>Errasti</surname><given-names>AE</given-names></name><name><surname>Gómez</surname><given-names>RM</given-names></name><name><surname>Jenne</surname><given-names>CN</given-names></name><name><surname>Carrera Silva</surname><given-names>EA</given-names></name><name><surname>Schattner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Platelets promote macrophage polarization toward pro-inflammatory phenotype and increase survival of septic mice</article-title><source>Cell Reports</source><volume>28</volume><fpage>896</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.06.062</pub-id><pub-id pub-id-type="pmid">31340152</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazenave</surname><given-names>JP</given-names></name><name><surname>Ohlmann</surname><given-names>P</given-names></name><name><surname>Cassel</surname><given-names>D</given-names></name><name><surname>Eckly</surname><given-names>A</given-names></name><name><surname>Hechler</surname><given-names>B</given-names></name><name><surname>Gachet</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Preparation of washed platelet suspensions from human and rodent blood</article-title><source>Methods in Molecular Biology</source><volume>272</volume><fpage>13</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1385/1-59259-782-3:013</pub-id><pub-id pub-id-type="pmid">15226531</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>HH</given-names></name><name><surname>Wang</surname><given-names>HG</given-names></name><name><surname>Kong</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>FM</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The effects of human platelet lysate on dental pulp stem cells derived from impacted human third molars</article-title><source>Biomaterials</source><volume>33</volume><fpage>5023</fpage><lpage>5035</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.03.057</pub-id><pub-id pub-id-type="pmid">22516606</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clemente</surname><given-names>D</given-names></name><name><surname>Ortega</surname><given-names>MC</given-names></name><name><surname>Arenzana</surname><given-names>FJ</given-names></name><name><surname>de Castro</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>FGF-2 and Anosmin-1 are selectively expressed in different types of multiple sclerosis lesions</article-title><source>The Journal of Neuroscience</source><volume>31</volume><fpage>14899</fpage><lpage>14909</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1158-11.2011</pub-id><pub-id pub-id-type="pmid">22016523</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cloutier</surname><given-names>N</given-names></name><name><surname>Paré</surname><given-names>A</given-names></name><name><surname>Farndale</surname><given-names>RW</given-names></name><name><surname>Schumacher</surname><given-names>HR</given-names></name><name><surname>Nigrovic</surname><given-names>PA</given-names></name><name><surname>Lacroix</surname><given-names>S</given-names></name><name><surname>Boilard</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Platelets can enhance vascular permeability</article-title><source>Blood</source><volume>120</volume><fpage>1334</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-02-413047</pub-id><pub-id pub-id-type="pmid">22544703</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Sousa</surname><given-names>DMB</given-names></name><name><surname>Benedetti</surname><given-names>A</given-names></name><name><surname>Altendorfer</surname><given-names>B</given-names></name><name><surname>Mrowetz</surname><given-names>H</given-names></name><name><surname>Unger</surname><given-names>MS</given-names></name><name><surname>Schallmoser</surname><given-names>K</given-names></name><name><surname>Aigner</surname><given-names>L</given-names></name><name><surname>Kniewallner</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Immune-mediated platelet depletion augments Alzheimer’s disease neuropathological hallmarks in APP-PS1 mice</article-title><source>Aging</source><volume>15</volume><fpage>630</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.18632/aging.204502</pub-id><pub-id pub-id-type="pmid">36734880</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Souza</surname><given-names>CS</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Luke Maxwell</surname><given-names>D</given-names></name><name><surname>Trusler</surname><given-names>O</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name><name><surname>Crewther</surname><given-names>S</given-names></name><name><surname>Peter</surname><given-names>K</given-names></name><name><surname>Orian</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Platelets drive inflammation and target gray matter and the retina in autoimmune-mediated encephalomyelitis</article-title><source>Journal of Neuropathology &amp; Experimental Neurology</source><volume>77</volume><fpage>567</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1093/jnen/nly032</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>AL</given-names></name><name><surname>Dalby</surname><given-names>A</given-names></name><name><surname>Foster</surname><given-names>HR</given-names></name><name><surname>Howard</surname><given-names>D</given-names></name><name><surname>Waller</surname><given-names>AK</given-names></name><name><surname>Taimoor</surname><given-names>M</given-names></name><name><surname>Lawrence</surname><given-names>M</given-names></name><name><surname>Mookerjee</surname><given-names>S</given-names></name><name><surname>Lehmann</surname><given-names>M</given-names></name><name><surname>Burton</surname><given-names>A</given-names></name><name><surname>Valdez</surname><given-names>J</given-names></name><name><surname>Thon</surname><given-names>J</given-names></name><name><surname>Italiano</surname><given-names>J</given-names></name><name><surname>Moreau</surname><given-names>T</given-names></name><name><surname>Ghevaert</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transfer to the clinic: refining forward programming of hPSCs to megakaryocytes for platelet production in bioreactors</article-title><source>Blood Advances</source><volume>5</volume><fpage>1977</fpage><lpage>1990</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2020003236</pub-id><pub-id pub-id-type="pmid">33843988</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fancy</surname><given-names>SPJ</given-names></name><name><surname>Baranzini</surname><given-names>SE</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Yuk</surname><given-names>D-I</given-names></name><name><surname>Irvine</surname><given-names>K-A</given-names></name><name><surname>Kaing</surname><given-names>S</given-names></name><name><surname>Sanai</surname><given-names>N</given-names></name><name><surname>Franklin</surname><given-names>RJM</given-names></name><name><surname>Rowitch</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS</article-title><source>Genes &amp; Development</source><volume>23</volume><fpage>1571</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1101/gad.1806309</pub-id><pub-id pub-id-type="pmid">19515974</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franklin</surname><given-names>RJM</given-names></name><name><surname>ffrench-Constant</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Remyelination in the CNS: from biology to therapy</article-title><source>Nature Reviews. Neuroscience</source><volume>9</volume><fpage>839</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1038/nrn2480</pub-id><pub-id pub-id-type="pmid">18931697</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Konradt</surname><given-names>C</given-names></name><name><surname>Corken</surname><given-names>A</given-names></name><name><surname>Ware</surname><given-names>J</given-names></name><name><surname>Nieswandt</surname><given-names>B</given-names></name><name><surname>Di Paola</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Nieman</surname><given-names>MT</given-names></name><name><surname>Whiteheart</surname><given-names>SW</given-names></name><name><surname>Brass</surname><given-names>LF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hemostasis vs. homeostasis: Platelets are essential for preserving vascular barrier function in the absence of injury or inflammation</article-title><source>PNAS</source><volume>117</volume><fpage>24316</fpage><lpage>24325</lpage><pub-id pub-id-type="doi">10.1073/pnas.2007642117</pub-id><pub-id pub-id-type="pmid">32929010</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>MH</given-names></name><name><surname>Hwang</surname><given-names>SI</given-names></name><name><surname>Roy</surname><given-names>DB</given-names></name><name><surname>Lundgren</surname><given-names>DH</given-names></name><name><surname>Price</surname><given-names>JV</given-names></name><name><surname>Ousman</surname><given-names>SS</given-names></name><name><surname>Fernald</surname><given-names>GH</given-names></name><name><surname>Gerlitz</surname><given-names>B</given-names></name><name><surname>Robinson</surname><given-names>WH</given-names></name><name><surname>Baranzini</surname><given-names>SE</given-names></name><name><surname>Grinnell</surname><given-names>BW</given-names></name><name><surname>Raine</surname><given-names>CS</given-names></name><name><surname>Sobel</surname><given-names>RA</given-names></name><name><surname>Han</surname><given-names>DK</given-names></name><name><surname>Steinman</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets</article-title><source>Nature</source><volume>451</volume><fpage>1076</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1038/nature06559</pub-id><pub-id pub-id-type="pmid">18278032</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiratsuka</surname><given-names>D</given-names></name><name><surname>Kurganov</surname><given-names>E</given-names></name><name><surname>Furube</surname><given-names>E</given-names></name><name><surname>Morita</surname><given-names>M</given-names></name><name><surname>Miyata</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>VEGF- and PDGF-dependent proliferation of oligodendrocyte progenitor cells in the medulla oblongata after LPC-induced focal demyelination</article-title><source>Journal of Neuroimmunology</source><volume>332</volume><fpage>176</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2019.04.016</pub-id><pub-id pub-id-type="pmid">31075641</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazanis</surname><given-names>I</given-names></name><name><surname>Feichtner</surname><given-names>M</given-names></name><name><surname>Lange</surname><given-names>S</given-names></name><name><surname>Rotheneichner</surname><given-names>P</given-names></name><name><surname>Hainzl</surname><given-names>S</given-names></name><name><surname>Öller</surname><given-names>M</given-names></name><name><surname>Schallmoser</surname><given-names>K</given-names></name><name><surname>Rohde</surname><given-names>E</given-names></name><name><surname>Reitsamer</surname><given-names>HA</given-names></name><name><surname>Couillard-Despres</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>H-C</given-names></name><name><surname>Franklin</surname><given-names>RJM</given-names></name><name><surname>Aigner</surname><given-names>L</given-names></name><name><surname>Rivera</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Lesion-induced accumulation of platelets promotes survival of adult neural stem / progenitor cells</article-title><source>Experimental Neurology</source><volume>269</volume><fpage>75</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2015.03.018</pub-id><pub-id pub-id-type="pmid">25819103</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kocovski</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>D’Souza</surname><given-names>CS</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Dang</surname><given-names>PT</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Peter</surname><given-names>K</given-names></name><name><surname>Hale</surname><given-names>MW</given-names></name><name><surname>Orian</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Platelet depletion is effective in ameliorating anxiety-like behavior and reducing the pro-inflammatory environment in the hippocampus in murine experimental autoimmune encephalomyelitis</article-title><source>Journal of Clinical Medicine</source><volume>8</volume><elocation-id>162</elocation-id><pub-id pub-id-type="doi">10.3390/jcm8020162</pub-id><pub-id pub-id-type="pmid">30717130</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotter</surname><given-names>MR</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Franklin</surname><given-names>RJM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression</article-title><source>Neurobiology of Disease</source><volume>18</volume><fpage>166</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2004.09.019</pub-id><pub-id pub-id-type="pmid">15649707</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotter</surname><given-names>MR</given-names></name><name><surname>Li</surname><given-names>W-W</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Franklin</surname><given-names>RJM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation</article-title><source>The Journal of Neuroscience</source><volume>26</volume><fpage>328</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2615-05.2006</pub-id><pub-id pub-id-type="pmid">16399703</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuenz</surname><given-names>B</given-names></name><name><surname>Lutterotti</surname><given-names>A</given-names></name><name><surname>Khalil</surname><given-names>M</given-names></name><name><surname>Ehling</surname><given-names>R</given-names></name><name><surname>Gneiss</surname><given-names>C</given-names></name><name><surname>Deisenhammer</surname><given-names>F</given-names></name><name><surname>Reindl</surname><given-names>M</given-names></name><name><surname>Berger</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis</article-title><source>Journal of Neuroimmunology</source><volume>167</volume><fpage>143</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2005.06.019</pub-id><pub-id pub-id-type="pmid">16040131</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langer</surname><given-names>HF</given-names></name><name><surname>Choi</surname><given-names>EY</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Schleicher</surname><given-names>R</given-names></name><name><surname>Chung</surname><given-names>KJ</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Göbel</surname><given-names>K</given-names></name><name><surname>Bdeir</surname><given-names>K</given-names></name><name><surname>Chatzigeorgiou</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>C</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name><name><surname>Kruhlak</surname><given-names>MJ</given-names></name><name><surname>Rose</surname><given-names>JW</given-names></name><name><surname>Burns</surname><given-names>JB</given-names></name><name><surname>Hill</surname><given-names>KE</given-names></name><name><surname>Qu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lehrmann</surname><given-names>E</given-names></name><name><surname>Becker</surname><given-names>KG</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Simon</surname><given-names>DI</given-names></name><name><surname>Nieswandt</surname><given-names>B</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Meuth</surname><given-names>SG</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis</article-title><source>Circulation Research</source><volume>110</volume><fpage>1202</fpage><lpage>1210</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.256370</pub-id><pub-id pub-id-type="pmid">22456181</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langer</surname><given-names>HF</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Platelets and neurovascular inflammation</article-title><source>Thrombosis and Haemostasis</source><volume>110</volume><fpage>888</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1160/TH13-02-0096</pub-id><pub-id pub-id-type="pmid">23636306</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Prins</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Grinfeld</surname><given-names>J</given-names></name><name><surname>Gonzalez-Arias</surname><given-names>C</given-names></name><name><surname>Loughran</surname><given-names>S</given-names></name><name><surname>Dovey</surname><given-names>OM</given-names></name><name><surname>Klampfl</surname><given-names>T</given-names></name><name><surname>Bennett</surname><given-names>C</given-names></name><name><surname>Hamilton</surname><given-names>TL</given-names></name><name><surname>Pask</surname><given-names>DC</given-names></name><name><surname>Sneade</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><name><surname>Aungier</surname><given-names>J</given-names></name><name><surname>Ghevaert</surname><given-names>C</given-names></name><name><surname>Vassiliou</surname><given-names>GS</given-names></name><name><surname>Kent</surname><given-names>DG</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage</article-title><source>Blood</source><volume>131</volume><fpage>649</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-09-806356</pub-id><pub-id pub-id-type="pmid">29282219</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lock</surname><given-names>C</given-names></name><name><surname>Hermans</surname><given-names>G</given-names></name><name><surname>Pedotti</surname><given-names>R</given-names></name><name><surname>Brendolan</surname><given-names>A</given-names></name><name><surname>Schadt</surname><given-names>E</given-names></name><name><surname>Garren</surname><given-names>H</given-names></name><name><surname>Langer-Gould</surname><given-names>A</given-names></name><name><surname>Strober</surname><given-names>S</given-names></name><name><surname>Cannella</surname><given-names>B</given-names></name><name><surname>Allard</surname><given-names>J</given-names></name><name><surname>Klonowski</surname><given-names>P</given-names></name><name><surname>Austin</surname><given-names>A</given-names></name><name><surname>Lad</surname><given-names>N</given-names></name><name><surname>Kaminski</surname><given-names>N</given-names></name><name><surname>Galli</surname><given-names>SJ</given-names></name><name><surname>Oksenberg</surname><given-names>JR</given-names></name><name><surname>Raine</surname><given-names>CS</given-names></name><name><surname>Heller</surname><given-names>R</given-names></name><name><surname>Steinman</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis</article-title><source>Nature Medicine</source><volume>8</volume><fpage>500</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1038/nm0502-500</pub-id><pub-id pub-id-type="pmid">11984595</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohmann</surname><given-names>M</given-names></name><name><surname>Walenda</surname><given-names>G</given-names></name><name><surname>Hemeda</surname><given-names>H</given-names></name><name><surname>Joussen</surname><given-names>S</given-names></name><name><surname>Drescher</surname><given-names>W</given-names></name><name><surname>Jockenhoevel</surname><given-names>S</given-names></name><name><surname>Hutschenreuter</surname><given-names>G</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e37839</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0037839</pub-id><pub-id pub-id-type="pmid">22662236</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcos-Ramiro</surname><given-names>B</given-names></name><name><surname>Oliva Nacarino</surname><given-names>P</given-names></name><name><surname>Serrano-Pertierra</surname><given-names>E</given-names></name><name><surname>Blanco-Gelaz</surname><given-names>MA</given-names></name><name><surname>Weksler</surname><given-names>BB</given-names></name><name><surname>Romero</surname><given-names>IA</given-names></name><name><surname>Couraud</surname><given-names>PO</given-names></name><name><surname>Tuñón</surname><given-names>A</given-names></name><name><surname>López-Larrea</surname><given-names>C</given-names></name><name><surname>Millán</surname><given-names>J</given-names></name><name><surname>Cernuda-Morollón</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Microparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier function</article-title><source>BMC Neuroscience</source><volume>15</volume><elocation-id>110</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2202-15-110</pub-id><pub-id pub-id-type="pmid">25242463</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miron</surname><given-names>VE</given-names></name><name><surname>Boyd</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>J-W</given-names></name><name><surname>Yuen</surname><given-names>TJ</given-names></name><name><surname>Ruckh</surname><given-names>JM</given-names></name><name><surname>Shadrach</surname><given-names>JL</given-names></name><name><surname>van Wijngaarden</surname><given-names>P</given-names></name><name><surname>Wagers</surname><given-names>AJ</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Franklin</surname><given-names>RJM</given-names></name><name><surname>ffrench-Constant</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination</article-title><source>Nature Neuroscience</source><volume>16</volume><fpage>1211</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1038/nn.3469</pub-id><pub-id pub-id-type="pmid">23872599</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morodomi</surname><given-names>Y</given-names></name><name><surname>Kanaji</surname><given-names>S</given-names></name><name><surname>Won</surname><given-names>E</given-names></name><name><surname>Ruggeri</surname><given-names>ZM</given-names></name><name><surname>Kanaji</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanisms of anti-GPIbα antibody-induced thrombocytopenia in mice</article-title><source>Blood</source><volume>135</volume><fpage>2292</fpage><lpage>2301</lpage><pub-id pub-id-type="doi">10.1182/blood.2019003770</pub-id><pub-id pub-id-type="pmid">32157300</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murtie</surname><given-names>JC</given-names></name><name><surname>Zhou</surname><given-names>YX</given-names></name><name><surname>Le</surname><given-names>TQ</given-names></name><name><surname>Vana</surname><given-names>AC</given-names></name><name><surname>Armstrong</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>PDGF and FGF2 pathways regulate distinct oligodendrocyte lineage responses in experimental demyelination with spontaneous remyelination</article-title><source>Neurobiology of Disease</source><volume>19</volume><fpage>171</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2004.12.006</pub-id><pub-id pub-id-type="pmid">15837572</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>B</given-names></name><name><surname>Baror</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Segel</surname><given-names>M</given-names></name><name><surname>Dietmann</surname><given-names>S</given-names></name><name><surname>Rawji</surname><given-names>KS</given-names></name><name><surname>Foerster</surname><given-names>S</given-names></name><name><surname>McClain</surname><given-names>CR</given-names></name><name><surname>Chalut</surname><given-names>K</given-names></name><name><surname>van Wijngaarden</surname><given-names>P</given-names></name><name><surname>Franklin</surname><given-names>RJM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metformin restores CNS remyelination capacity by rejuvenating aged stem cells</article-title><source>Cell Stem Cell</source><volume>25</volume><fpage>473</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2019.08.015</pub-id><pub-id pub-id-type="pmid">31585093</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noseworthy</surname><given-names>JH</given-names></name><name><surname>Lucchinetti</surname><given-names>C</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name><name><surname>Weinshenker</surname><given-names>BG</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Multiple sclerosis</article-title><source>The New England Journal of Medicine</source><volume>343</volume><fpage>938</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1056/NEJM200009283431307</pub-id><pub-id pub-id-type="pmid">11006371</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurden</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Platelets, inflammation and tissue regeneration</article-title><source>Thrombosis and Haemostasis</source><volume>105 Suppl 1</volume><fpage>S13</fpage><lpage>S33</lpage><pub-id pub-id-type="doi">10.1160/THS10-11-0720</pub-id><pub-id pub-id-type="pmid">21479340</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>MA</given-names></name><name><surname>Ryu</surname><given-names>JK</given-names></name><name><surname>Chang</surname><given-names>KJ</given-names></name><name><surname>Etxeberria</surname><given-names>A</given-names></name><name><surname>Bardehle</surname><given-names>S</given-names></name><name><surname>Mendiola</surname><given-names>AS</given-names></name><name><surname>Kamau-Devers</surname><given-names>W</given-names></name><name><surname>Fancy</surname><given-names>SPJ</given-names></name><name><surname>Thor</surname><given-names>A</given-names></name><name><surname>Bushong</surname><given-names>EA</given-names></name><name><surname>Baeza-Raja</surname><given-names>B</given-names></name><name><surname>Syme</surname><given-names>CA</given-names></name><name><surname>Wu</surname><given-names>MD</given-names></name><name><surname>Rios Coronado</surname><given-names>PE</given-names></name><name><surname>Meyer-Franke</surname><given-names>A</given-names></name><name><surname>Yahn</surname><given-names>S</given-names></name><name><surname>Pous</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Schachtrup</surname><given-names>C</given-names></name><name><surname>Lassmann</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>EJ</given-names></name><name><surname>Han</surname><given-names>MH</given-names></name><name><surname>Absinta</surname><given-names>M</given-names></name><name><surname>Reich</surname><given-names>DS</given-names></name><name><surname>Ellisman</surname><given-names>MH</given-names></name><name><surname>Rowitch</surname><given-names>DH</given-names></name><name><surname>Chan</surname><given-names>JR</given-names></name><name><surname>Akassoglou</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Fibrinogen activates BMP signaling in oligodendrocyte progenitor cells and inhibits remyelination after vascular damage</article-title><source>Neuron</source><volume>96</volume><fpage>1003</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.10.008</pub-id><pub-id pub-id-type="pmid">29103804</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolfes</surname><given-names>V</given-names></name><name><surname>Ribeiro</surname><given-names>LS</given-names></name><name><surname>Hawwari</surname><given-names>I</given-names></name><name><surname>Böttcher</surname><given-names>L</given-names></name><name><surname>Rosero</surname><given-names>N</given-names></name><name><surname>Maasewerd</surname><given-names>S</given-names></name><name><surname>Santos</surname><given-names>MLS</given-names></name><name><surname>Próchnicki</surname><given-names>T</given-names></name><name><surname>Silva</surname><given-names>CS</given-names></name><name><surname>Wanderley</surname><given-names>CS</given-names></name><name><surname>Rothe</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>SV</given-names></name><name><surname>Stunden</surname><given-names>HJ</given-names></name><name><surname>Bertheloot</surname><given-names>D</given-names></name><name><surname>Rivas</surname><given-names>MN</given-names></name><name><surname>Fontes</surname><given-names>CJ</given-names></name><name><surname>Carvalho</surname><given-names>LH</given-names></name><name><surname>Cunha</surname><given-names>FQ</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Arditi</surname><given-names>M</given-names></name><name><surname>Franklin</surname><given-names>BS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Platelets fuel the inflammasome activation of innate immune cells</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107615</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107615</pub-id><pub-id pub-id-type="pmid">32402278</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rüther</surname><given-names>BJ</given-names></name><name><surname>Scheld</surname><given-names>M</given-names></name><name><surname>Dreymueller</surname><given-names>D</given-names></name><name><surname>Clarner</surname><given-names>T</given-names></name><name><surname>Kress</surname><given-names>E</given-names></name><name><surname>Brandenburg</surname><given-names>L-O</given-names></name><name><surname>Swartenbroekx</surname><given-names>T</given-names></name><name><surname>Hoornaert</surname><given-names>C</given-names></name><name><surname>Ponsaerts</surname><given-names>P</given-names></name><name><surname>Fallier-Becker</surname><given-names>P</given-names></name><name><surname>Beyer</surname><given-names>C</given-names></name><name><surname>Rohr</surname><given-names>SO</given-names></name><name><surname>Schmitz</surname><given-names>C</given-names></name><name><surname>Chrzanowski</surname><given-names>U</given-names></name><name><surname>Hochstrasser</surname><given-names>T</given-names></name><name><surname>Nyamoya</surname><given-names>S</given-names></name><name><surname>Kipp</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Combination of cuprizone and experimental autoimmune encephalomyelitis to study inflammatory brain lesion formation and progression</article-title><source>Glia</source><volume>65</volume><fpage>1900</fpage><lpage>1913</lpage><pub-id pub-id-type="doi">10.1002/glia.23202</pub-id><pub-id pub-id-type="pmid">28836302</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sáenz-Cuesta</surname><given-names>M</given-names></name><name><surname>Irizar</surname><given-names>H</given-names></name><name><surname>Castillo-Triviño</surname><given-names>T</given-names></name><name><surname>Muñoz-Culla</surname><given-names>M</given-names></name><name><surname>Osorio-Querejeta</surname><given-names>I</given-names></name><name><surname>Prada</surname><given-names>A</given-names></name><name><surname>Sepúlveda</surname><given-names>L</given-names></name><name><surname>López-Mato</surname><given-names>MP</given-names></name><name><surname>López de Munain</surname><given-names>A</given-names></name><name><surname>Comabella</surname><given-names>M</given-names></name><name><surname>Villar</surname><given-names>LM</given-names></name><name><surname>Olascoaga</surname><given-names>J</given-names></name><name><surname>Otaegui</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis</article-title><source>Biomarkers in Medicine</source><volume>8</volume><fpage>653</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.2217/bmm.14.9</pub-id><pub-id pub-id-type="pmid">25123034</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>H</given-names></name><name><surname>Thompson</surname><given-names>RH</given-names></name><name><surname>Wright</surname><given-names>HP</given-names></name><name><surname>Zilkha</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="1968">1968</year><article-title>Further studies on platelet adhesiveness and serum cholesteryl linoleate levels in multiple sclerosis</article-title><source>Journal of Neurology, Neurosurgery, and Psychiatry</source><volume>31</volume><fpage>321</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1136/jnnp.31.4.321</pub-id><pub-id pub-id-type="pmid">5684391</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schallmoser</surname><given-names>K</given-names></name><name><surname>Strunk</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Generation of a pool of human platelet lysate and efficient use in cell culture</article-title><source>Methods in Molecular Biology</source><volume>946</volume><fpage>349</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1007/978-1-62703-128-8_22</pub-id><pub-id pub-id-type="pmid">23179843</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semple</surname><given-names>JW</given-names></name><name><surname>Italiano</surname><given-names>JE</given-names></name><name><surname>Freedman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Platelets and the immune continuum</article-title><source>Nature Reviews. Immunology</source><volume>11</volume><fpage>264</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1038/nri2956</pub-id><pub-id pub-id-type="pmid">21436837</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheremata</surname><given-names>WA</given-names></name><name><surname>Jy</surname><given-names>W</given-names></name><name><surname>Horstman</surname><given-names>LL</given-names></name><name><surname>Ahn</surname><given-names>YS</given-names></name><name><surname>Alexander</surname><given-names>JS</given-names></name><name><surname>Minagar</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Evidence of platelet activation in multiple sclerosis</article-title><source>Journal of Neuroinflammation</source><volume>5</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.1186/1742-2094-5-27</pub-id><pub-id pub-id-type="pmid">18588683</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>DI</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Inflammation and vascular injury: basic discovery to drug development</article-title><source>Circulation Journal</source><volume>76</volume><fpage>1811</fpage><lpage>1818</lpage><pub-id pub-id-type="doi">10.1253/circj.cj-12-0801</pub-id><pub-id pub-id-type="pmid">22785436</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinman</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Platelets provide a bounty of potential targets for therapy in multiple sclerosis</article-title><source>Circulation Research</source><volume>110</volume><fpage>1157</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.112.269050</pub-id><pub-id pub-id-type="pmid">22539752</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>HH</given-names></name><name><surname>Niu</surname><given-names>J</given-names></name><name><surname>Munji</surname><given-names>R</given-names></name><name><surname>Davalos</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Tien</surname><given-names>AC</given-names></name><name><surname>Kuo</surname><given-names>CJ</given-names></name><name><surname>Chan</surname><given-names>JR</given-names></name><name><surname>Daneman</surname><given-names>R</given-names></name><name><surname>Fancy</surname><given-names>SPJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oligodendrocyte precursors migrate along vasculature in the developing nervous system</article-title><source>Science</source><volume>351</volume><fpage>379</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1126/science.aad3839</pub-id><pub-id pub-id-type="pmid">26798014</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warnke</surname><given-names>PH</given-names></name><name><surname>Humpe</surname><given-names>A</given-names></name><name><surname>Strunk</surname><given-names>D</given-names></name><name><surname>Stephens</surname><given-names>S</given-names></name><name><surname>Warnke</surname><given-names>F</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Schallmoser</surname><given-names>K</given-names></name><name><surname>Alamein</surname><given-names>M</given-names></name><name><surname>Bourke</surname><given-names>R</given-names></name><name><surname>Heiner</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies</article-title><source>Journal of Cranio-Maxillo-Facial Surgery</source><volume>41</volume><fpage>153</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.jcms.2012.07.003</pub-id><pub-id pub-id-type="pmid">22878221</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodruff</surname><given-names>RH</given-names></name><name><surname>Fruttiger</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>WD</given-names></name><name><surname>Franklin</surname><given-names>RJM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination</article-title><source>Molecular and Cellular Neurosciences</source><volume>25</volume><fpage>252</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2003.10.014</pub-id><pub-id pub-id-type="pmid">15019942</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>YX</given-names></name><name><surname>Flint</surname><given-names>NC</given-names></name><name><surname>Murtie</surname><given-names>JC</given-names></name><name><surname>Le</surname><given-names>TQ</given-names></name><name><surname>Armstrong</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Retroviral lineage analysis of fibroblast growth factor receptor signaling in FGF2 inhibition of oligodendrocyte progenitor differentiation</article-title><source>Glia</source><volume>54</volume><fpage>578</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1002/glia.20410</pub-id><pub-id pub-id-type="pmid">16921523</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The blood-brain barrier in health and chronic neurodegenerative disorders</article-title><source>Neuron</source><volume>57</volume><fpage>178</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2008.01.003</pub-id><pub-id pub-id-type="pmid">18215617</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91757.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ryu</surname><given-names>Vitaly</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study aims to understand how the regulation of oligodendrocyte progenitor cell (OPC) remyelination and function contributes to the treatment of multiple sclerosis. The authors provide <bold>convincing</bold> evidence for the platelets mediating OPC differentiation and remyelination. This work will be of interest to several disciplines.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91757.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors have studied the effects of platelets in OPC biology and remyelination. For this, they used mutant mice with lower levels of platelets as a demyelinating/remyelinating scenario, as well as in a model with large numbers of circulating platelets.</p><p>Strengths:</p><p>-The work is very focused, with defined objectives.</p><p>-The work is properly done.</p><p>Revision comments:</p><p>Having consulted the new version of the work by Amber et al., the modifications and the point-by-point cover letter explaining them give direct answers to my previous comments.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91757.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This paper examined whether circulating platelets regulate oligodendrocyte progenitor cell (OPC) differentiation for the link with multiple sclerosis (MS). They identified that the interaction with platelets enhances OPC differentiation although persistent contact inhibits the process in the long-term. The mouse model with increased platelet levels in the blood reduced mature oligodendrocytes, while how platelets might regulate OPC differentiation is not clear yet.</p><p>Strengths:</p><p>The use of both partial platelet depletion and thrombocytosis mouse models gives in vivo evidence. The presentation of platelet accumulation in a time-course manner is rigorous. The in vitro co-culture model tested the role of platelets in OPC differentiation, which was supportive of in vivo observations.</p><p>Revision comments:</p><p>Although the mechanisms are limited, the authors addressed the major experiments I suggested.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91757.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Philp</surname><given-names>Amber R</given-names></name><role specific-use="author">Author</role><aff><institution>Austral University of Chile</institution><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff></contrib><contrib contrib-type="author"><name><surname>Reyes</surname><given-names>Carolina R</given-names></name><role specific-use="author">Author</role><aff><institution>University of Helsinki</institution><addr-line><named-content content-type="city">Helsinki</named-content></addr-line><country>Finland</country></aff></contrib><contrib contrib-type="author"><name><surname>Mansilla</surname><given-names>Josselyne</given-names></name><role specific-use="author">Author</role><aff><institution>Austral University of Chile</institution><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Amar</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Chao</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Valenzuela-Krugmann</surname><given-names>Carlos</given-names></name><role specific-use="author">Author</role><aff><institution>Austral University of Chile</institution><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff></contrib><contrib contrib-type="author"><name><surname>Rawji</surname><given-names>Khalil S</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Gonzalez Martinez</surname><given-names>Ginez A</given-names></name><role specific-use="author">Author</role><aff><institution>LifeArc</institution><addr-line><named-content content-type="city">Stevenage</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Dimas</surname><given-names>Penelope</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Hinrichsen</surname><given-names>Bryan</given-names></name><role specific-use="author">Author</role><aff><institution>Austral University of Chile</institution><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff></contrib><contrib contrib-type="author"><name><surname>Ulloa-Leal</surname><given-names>César</given-names></name><role specific-use="author">Author</role><aff><institution>Viña del Mar University</institution><addr-line><named-content content-type="city">Viña del Mar</named-content></addr-line><country>Chile</country></aff></contrib><contrib contrib-type="author"><name><surname>Waller</surname><given-names>Amie K</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Bessa de Sousa</surname><given-names>Diana M</given-names></name><role specific-use="author">Author</role><aff><institution>Paracelsus Medical University</institution><addr-line><named-content content-type="city">Salzburg</named-content></addr-line><country>Austria</country></aff></contrib><contrib contrib-type="author"><name><surname>Castro</surname><given-names>Maite A</given-names></name><role specific-use="author">Author</role><aff><institution>Austral University of Chile</institution><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff></contrib><contrib contrib-type="author"><name><surname>Aigner</surname><given-names>Ludwig</given-names></name><role specific-use="author">Author</role><aff><institution>Paracelsus Medical University Salzburg</institution><addr-line><named-content content-type="city">Salzburg</named-content></addr-line><country>Austria</country></aff></contrib><contrib contrib-type="author"><name><surname>Ehrenfeld</surname><given-names>Pamela</given-names></name><role specific-use="author">Author</role><aff><institution>Institute of Anatomy, Histology, and Pathology, Faculty of Medicine, Universidad Austral de Chile</institution><addr-line><named-content content-type="city">Valdivia</named-content></addr-line><country>Chile</country></aff></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Maria Elena</given-names></name><role specific-use="author">Author</role><aff><institution>University of Helsinki</institution><addr-line><named-content content-type="city">Helsinki</named-content></addr-line><country>Finland</country></aff></contrib><contrib contrib-type="author"><name><surname>Kazanis</surname><given-names>Ilias</given-names></name><role specific-use="author">Author</role><aff><institution>University of Westminster</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Ghevaert</surname><given-names>Cedric</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Franklin</surname><given-names>Robin JM</given-names></name><role specific-use="author">Author</role><aff><institution>Altos Labs, Cambridge Institute</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Rivera</surname><given-names>Francisco J</given-names></name><role specific-use="author">Author</role><aff><institution>University of Helsinki</institution><addr-line><named-content content-type="city">Helsinki</named-content></addr-line><country>Finland</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>The authors have studied the effects of platelets in OPC biology and remyelination. For this, they used mutant mice with lower levels of platelets as a demyelinating/remyelinating scenario, as well as in a model with large numbers of circulating platelets.</p><p>Strengths:</p><p>-The work is very focused, with defined objectives.</p><p>-The work is properly done.</p><p>Weaknesses:</p><p>-There is no clear effect on a single cell type and/or mechanism involved.</p></disp-quote><p>We appreciate the reviewer’s feedback. We understand that from our in vivo studies we are unable to distinguish whether the effects of platelets are directly exerted on OPCs or indirectly through a different cell type. However, data obtained from the platelet depleted model as well as the new data provided in this revised version in CALRHet mice indicate that, at least, macrophages / microglia do not contribute to the observed effects in OPCs. In addition to this, in vitro data support the direct effects of platelets on OPC function.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>This paper examined whether circulating platelets regulate oligodendrocyte progenitor cell (OPC) differentiation for the link with multiple sclerosis (MS). They identified that the interaction with platelets enhances OPC differentiation although persistent contact inhibits the process in the longterm. The mouse model with increased platelet levels in the blood reduced mature oligodendrocytes, while how platelets might regulate OPC differentiation is not clear yet.</p><p>Strengths:</p><p>The use of both partial platelet depletion and thrombocytosis mouse models gives in vivo evidence. The presentation of platelet accumulation in a time-course manner is rigorous. The in vitro co-culture model tested the role of platelets in OPC differentiation, which was supportive of in vivo observations.</p><p>Weaknesses:</p><p>How platelets regulate OPC differentiation is not clear. What the significance of platelets is in MS progression is not clear.</p></disp-quote><p>We thank reviewer’s view and assessment of our manuscript. We understand both of the reviewer’s concerns. Firstly, we performed additional in vitro studies and we have confirmed that platelet-contained factors are, at least in part, responsible for modulating OPC differentiation and, thus, direct cell-cell contact is not essential. Secondly, in this revised version, we added references arguing that the plasma levels of platelet microparticles and platelet-specific factors correlate with MS progression and severity.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For the Authors):</bold></p><p>To ameliorate the quality of their work and make it suitable for its publication in eLife, I strongly suggest the authors to:</p><p>(1) In vitro co-culture platelets and OPCs to check the effects on this latter cell type biology.</p><p>Response: We have performed in vitro studies, in which OPCs were co-cultured with washed platelets (WP). We observed that OPC differentiation was boosted after a short exposure to WP, however, prolonged exposure to WP suppressed this effect (revised Figure 3A and B). Also, our new data using platelet lysate (PL) indicate that platelet-contained molecules are responsible for this effect (revised Figure 3C and D). Finally, we showed that by removing PL after sustained exposure (6 DIV) the ability of platelets to promote OPC differentiation is rescued (revised Figure 3E and F).</p><p>(2) In the CALR model, can the authors check effect of chronic exposure to large numbers of platelets? Is this affecting macrophages (including their polarization)?</p><p>Response: Yes, compared to wild type mouse, in the CALRHET model we confirmed the presence of larger number of platelets within demyelinated lesions (Figure 4A and C). Also, in this revised version we added data showing in the CALRHET model that thrombocytosis does not affect macrophage / microglia numbers and polarization (revised Supplementary Figure 2).</p><p>(3) Some aspects of the Introduction section seems too old-fashioned (ex.: the use of bFGF instead of FGF2 to refer to Fibroblast Growth Factor 2), as well as it would be convenient to include more recent references on the role of FGF2 and PDGFa in OPC biology.</p><p>Response: We agree with the reviewer. In this revised version we have changed bFGF for FGF2 and we added more recent references addressing the role of FGF2 and PDGFa in OPC biology.</p><p>(4) There are some constructions and typos that could be corrected.</p><p>Response: We have checked language constructions as well as typos, and these have been corrected.</p><p>(5) Please revise spelling of some names in the bibliography list (ex.: the correct surname is ffrenchConstant, not Ffrench-Constant).</p></disp-quote><p>We have revised the spelling of names within the bibliography, and we have corrected them accordingly.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For the Authors):</bold></p><p>Mechanisms of platelet-OPC interactions</p><p>- transwell co-culture assay will examine if the OPC phenotype is through direct or indirect interactions with platelets;</p></disp-quote><p>We have performed additional in vitro studies, in which OPCs were exposed to platelet lysate (PL). New results indicate that a short exposure to PL can promote OPC differentiation (revised Figure 3C and D), while a sustained exposure supresses this effect (revised Figure 3E and F). These findings indicate that platelet-contained factors are, at least in part, responsible for modulating OPC differentiation and, thus, direct cell-cell contact is not essential for such an effect.</p><disp-quote content-type="editor-comment"><p>- can you revert the phenotype of OPCs co-cultured long with platelets (maturation blocked) by removing platelet (then OPC differentiate again?) to see if the phenotype is reversible or not?</p></disp-quote><p>We would like to thank the reviewer for bringing up this interesting question. We have performed additional in vitro studies to address this issue. We found that by removing PL upon 6-days of sustained exposure rescues the ability of platelets to promote OPC differentiation (revised Figure 3E and F). These findings indicate that the supressing effect of prolonged exposure to platelets in OPC differentiation is reversible.</p><disp-quote content-type="editor-comment"><p>Clinical correlation</p><p>- How many MS patients has an abnormal number of or exposure to platelets?</p><p>We have added new information in the introduction section. Indeed, previous studies have shown that MS patients display higher levels of circulating platelet microparticles (PMPs) (MarcosRamiro et al., 2014) as well as increased plasma levels of platelet-specific factors such as, P-selectin and PF4 (Cananzi et al., 1987; Kuenz et al., 2005).</p><p>do platelets amount correlate with diseases severeness?</p></disp-quote><p>We have added new information in the introduction section. Indeed, PMPs are indicative of the clinical status of the disease (Saenz-Cuesta et al., 2014). Also, plasma levels of P-selectin and PF4 correlate with disease course and severity, respectively (Cananzi et al., 1987; Kuenz et al., 2005).</p><disp-quote content-type="editor-comment"><p>Image quantification</p><p>- please state how many sections were counted. How many animals were used per condition. Is the practice of blinded observers done for each dataset?</p></disp-quote><p>We added this information in the figure legends and in methods section. We counted between 3-5 sections per lesion. We used 3 to 6 animals per experimental group and data was analysed by blinded observers.</p></body></sub-article></article>